e-Therapeutics plc Investor Presentation
October 20 2021 - 01:00AM
RNS Non-Regulatory
TIDMETX
e-Therapeutics plc
20 October 2021
e-therapeutics plc
("e-therapeutics" or the "Company")
Investor Presentation
Oxford, UK, 20 October 2021 - e-therapeutics plc (AIM: ETX;
OTCQX; ETXPF), a specialist in computational drug discovery with a
focus on developing RNA interference ("RNAi") therapeutics, is
pleased to announce that Ali Mortazavi, CEO, will provide a live
presentation relating to the Company's Interim results for the six
months ended 31 July 2021 via the Investor Meet Company platform on
26 October 2021 at 4.30 p.m. BST.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9.00 a.m. the day before
the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet e-therapeutics plc via:
https://www.investormeetcompany.com/e-therapeutics-plc/register-investor
Investors who already follow e-therapeutics plc on the Investor
Meet Company platform will automatically be invited.
Enquiries :
e-therapeutics plc Tel: +44 (0)1993 883
125
Ali Mortazavi, CEO www.etherapeutics.co.uk
Karl Keegan, CFO
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate
Broking)
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company integrating
computational power and biology to accelerate the discovery of
life-transforming medicines. The Company has developed and
validated a powerful, disease and modality agnostic computational
approach to drug discovery, leveraging its industry-leading
expertise in network biology to fully capture and interrogate human
disease complexity.
The Company's multi-disciplinary team builds computational
models of biological functions to transform the search for new
medicines, interventions, mechanisms and genetic support. Our
biology-led in silico laboratory enables rapid hypothesis
generation and phenotypic screening of millions of compounds
leading to 100-1000x higher hit rates in the wet lab and successful
mode of action elucidation. Novel targets can also be identified,
prioritised and assessed. Harnessing internal target gene
discoveries, e-therapeutics is currently building an in-house
pipeline of RNAi based medicines, using its proprietary
GalNAc-siRNA technology.
e-therapeutics has deployed and validated its disease-agnostic
computational drug discovery platform both in house and with
partners, including Novo Nordisk, Galapagos NV and a US-based, top
5 pharmaceutical company.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEASENFDKFFFA
(END) Dow Jones Newswires
October 20, 2021 02:00 ET (06:00 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Feb 2024 to Mar 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Mar 2023 to Mar 2024